Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

ClinicalTrials.gov ID: NCT00803374

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00803374. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Multiple Ascending Dose Study of BMS-663513 (Anti CD137) in Combination With Ipilimumab (BMS-734016/Anti-CTLA-4) in Subjects With Unresectable Stage III or Stage IV Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable

Study identification

NCT ID: NCT00803374
Recruitment status: Withdrawn
Study type: Interventional
Phase: Phase 1
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Melanoma

Interventions

AntiCD137 Drug
Ipilimumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2010 (Type not available)
Primary completion: Jul 2012 (Estimated)
Completion: Jan 2013 (Estimated)
Last update posted: Nov 21, 2011

2010 – 2013

United States locations

U.S. sites: 7
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Local Institution	Los Angeles	California	90025	—
Local Institution	New Haven	Connecticut	06520	—
Local Institution	Tampa	Florida	33612	—
Local Institution	Boston	Massachusetts	02114	—
Local Institution	Boston	Massachusetts	02115	—
Local Institution	Boston	Massachusetts	02215	—
Local Institution	New York	New York	10021	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00803374, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 21, 2011 · Synced Nov 15, 2026